MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the successful transfer and rewrite of all its intellectual property protections to cover a newly developed crystalline form of its lead drug candidate, buntanetap. The move solidifies patent coverage for both the original and crystal versions of the compound through 2046.
The company originally built its IP portfolio around a semi-crystalline form of buntanetap, targeting chronic neurodegenerative diseases such as Alzheimer’s and Parkinson’s. With the discovery of a new crystalline form—offering improved solid-state stability while maintaining comparable pharmacokinetic properties—Annovis has now ensured that all patent families reflect this development. The updated patents encompass composition of matter, mechanism of action, multiple therapeutic indications, and potential drug combinations.
“This is a major milestone for our company,” said Annovis President and CEO Maria Maccecchini, Ph.D. “With full IP protection now in place for both forms of buntanetap, we are well-positioned to continue its development and fully explore its therapeutic potential.”
Animal and human studies have confirmed bioequivalence between the original and crystal forms, showing identical systemic exposure. These findings were recently presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto.
The U.S. Food and Drug Administration approved the crystalline form of buntanetap for use in Annovis’s pivotal Phase 3 clinical trial for early-stage Alzheimer’s disease last year. The trial (NCT06709014) is currently enrolling participants who meet specified clinical and biomarker criteria. Patients are randomized to receive either placebo or crystal buntanetap daily over an 18-month period. To date, more than 75 trial sites have been activated across the U.S., with enrollment continuing to accelerate.
Buntanetap’s mechanism of action targets multiple neurotoxic proteins simultaneously—an approach Annovis believes could yield superior therapeutic outcomes. The company is also exploring synergistic combinations with GLP-1 agonists, PDE5 inhibitors, and statins as part of its broader development strategy.
The comprehensive IP transition marks a key step for Annovis as it prepares for potential commercialization and considers pipeline expansions beyond neurodegeneration.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.